Celularity Inc (CELU)

$3.38

+0.17

(+5.3%)▲

Market is closed - opens 7 PM, 25 Apr 2024

Insights on Celularity Inc

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 2.93M → 3.78M (in $), with an average increase of 11.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -47.94M → -93.87M (in $), with an average decrease of 47.9% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 52.6% return, outperforming this stock by 100.4%

Performance

  • $3.21
    $3.44
    $3.38
    downward going graph

    5.03%

    Downside

    Day's Volatility :6.69%

    Upside

    1.74%

    downward going graph
  • $1.59
    $8.90
    $3.38
    downward going graph

    52.96%

    Downside

    52 Weeks Volatility :82.13%

    Upside

    62.02%

    downward going graph

Returns

PeriodCelularity IncSector (Health Care)Index (Russel 2000)
3 Months
7.0%
2.0%
0.0%
6 Months
62.04%
11.7%
0.0%
1 Year
-47.82%
5.8%
1.3%
3 Years
-68.34%
14.2%
-22.1%

Highlights

Market Capitalization
66.7M
Book Value
$1.56
Earnings Per Share (EPS)
-10.3
Wall Street Target Price
2.5
Profit Margin
0.0%
Operating Margin TTM
-430.51%
Return On Assets TTM
-20.48%
Return On Equity TTM
-186.55%
Revenue TTM
14.8M
Revenue Per Share TTM
0.89
Quarterly Revenue Growth YOY
-8.4%
Gross Profit TTM
-1.7M
EBITDA
-87.9M
Diluted Eps TTM
-10.3
Quarterly Earnings Growth YOY
-0.92
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Celularity Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Downside of 26.04%

Current $3.38
Target $2.50

Company Financials

FY19Y/Y Change
Revenue
21.1M
-
Net Income
5.9M
-
Net Profit Margin
27.8%
-
FY20Y/Y Change
Revenue
14.3M
↓ 32.48%
Net Income
-208.2M
↓ 3642.12%
Net Profit Margin
-1.5K%
↓ 1486.22%
FY21Y/Y Change
Revenue
21.3M
↑ 49.43%
Net Income
-100.1M
↓ 51.92%
Net Profit Margin
-469.27%
↑ 989.15%
FY22Y/Y Change
Revenue
18.0M
↓ 15.75%
Net Income
14.2M
↓ 114.18%
Net Profit Margin
78.95%
↑ 548.22%
FY23Y/Y Change
Revenue
14.8M
↓ 17.73%
Net Income
-181.4M
↓ 1378.24%
Net Profit Margin
-1.2K%
↓ 1305.67%
Q3 FY22Q/Q Change
Revenue
4.1M
↑ 9.51%
Net Income
4.8M
↓ 89.97%
Net Profit Margin
116.06%
↓ 1150.52%
Q4 FY22Q/Q Change
Revenue
4.1M
↓ 0.15%
Net Income
24.4M
↑ 409.15%
Net Profit Margin
591.77%
↑ 475.71%
Q1 FY23Q/Q Change
Revenue
3.9M
↓ 4.7%
Net Income
-64.0M
↓ 362.0%
Net Profit Margin
-1.6K%
↓ 2218.63%
Q2 FY23Q/Q Change
Revenue
2.9M
↓ 25.34%
Net Income
-47.9M
↓ 25.1%
Net Profit Margin
-1.6K%
↓ 5.17%
Q3 FY23Q/Q Change
Revenue
3.8M
↑ 28.86%
Net Income
-93.9M
↑ 95.78%
Net Profit Margin
-2.5K%
↓ 847.53%
Q4 FY23Q/Q Change
Revenue
3.8M
↑ 0.0%
Net Income
-93.9M
↑ 0.0%
Net Profit Margin
-2.5K%
↑ 0.0%
FY18Y/Y Change
Total Assets
174.5K
-
Total Liabilities
150.6K
-
FY19Y/Y Change
Total Assets
291.6M
↑ 167050.27%
Total Liabilities
28.2M
↑ 18638.4%
FY20Y/Y Change
Total Assets
431.0M
↑ 47.81%
Total Liabilities
962.4M
↑ 3311.39%
FY21Y/Y Change
Total Assets
414.1M
↓ 3.92%
Total Liabilities
314.7M
↓ 67.3%
FY22Y/Y Change
Total Assets
401.1M
↓ 3.15%
Total Liabilities
202.2M
↓ 35.76%
Q3 FY22Q/Q Change
Total Assets
437.1M
↑ 1.81%
Total Liabilities
272.9M
↓ 2.26%
Q4 FY22Q/Q Change
Total Assets
401.1M
↓ 8.25%
Total Liabilities
202.2M
↓ 25.91%
Q1 FY23Q/Q Change
Total Assets
362.4M
↓ 9.64%
Total Liabilities
206.8M
↑ 2.29%
Q2 FY23Q/Q Change
Total Assets
246.4M
↓ 32.01%
Total Liabilities
127.9M
↓ 38.14%
Q3 FY23Q/Q Change
Total Assets
157.2M
↓ 36.21%
Total Liabilities
126.9M
↓ 0.76%
Q4 FY23Q/Q Change
Total Assets
157.2M
↑ 0.0%
Total Liabilities
126.9M
↑ 0.0%
FY18Y/Y Change
Operating Cash Flow
-60.0M
-
Investing Cash Flow
-31.2M
-
Financing Cash Flow
77.5M
-
FY19Y/Y Change
Operating Cash Flow
-1.1M
↓ 98.17%
Investing Cash Flow
-31.5M
↑ 0.93%
Financing Cash Flow
288.8M
↑ 272.46%
FY20Y/Y Change
Operating Cash Flow
-63.2M
↑ 5656.16%
Investing Cash Flow
578.7K
↓ 101.84%
Financing Cash Flow
102.0M
↓ 64.68%
FY21Y/Y Change
Operating Cash Flow
-110.1M
↑ 74.22%
Investing Cash Flow
-5.9M
↓ 1120.04%
Financing Cash Flow
98.6M
↓ 3.38%
FY22Y/Y Change
Operating Cash Flow
-137.9M
↑ 25.23%
Investing Cash Flow
-5.2M
↓ 11.3%
Financing Cash Flow
119.8M
↑ 21.59%
Q3 FY22Q/Q Change
Operating Cash Flow
-37.7M
↑ 3.86%
Investing Cash Flow
-1.6M
↑ 8.54%
Financing Cash Flow
43.9M
↑ 58.52%
Q4 FY22Q/Q Change
Operating Cash Flow
-29.6M
↓ 21.57%
Investing Cash Flow
-779.0K
↓ 50.16%
Financing Cash Flow
1.7M
↓ 96.17%
Q1 FY23Q/Q Change
Operating Cash Flow
-15.0M
↓ 49.32%
Investing Cash Flow
-3.2M
↑ 311.94%
Financing Cash Flow
12.8M
↑ 657.21%
Q2 FY23Q/Q Change
Operating Cash Flow
-11.0M
↓ 26.46%
Investing Cash Flow
-31.0K
↓ 99.03%
Financing Cash Flow
5.6M
↓ 56.03%

Technicals Summary

Sell

Neutral

Buy

Celularity Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Celularity Inc
Celularity Inc
-39.09%
62.04%
-47.82%
-68.34%
-68.34%
Moderna, Inc.
Moderna, Inc.
-2.26%
35.27%
-21.9%
-39.25%
318.83%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-5.59%
12.81%
13.84%
81.04%
166.5%
Novo Nordisk A/s
Novo Nordisk A/s
-0.32%
31.91%
50.92%
247.21%
431.9%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.67%
11.53%
21.99%
86.62%
131.89%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Celularity Inc
Celularity Inc
2.28
NA
NA
0.0
-1.87
-0.2
NA
1.56
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.9
25.9
1.46
45.02
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
47.09
47.09
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.81
28.81
0.53
16.76
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Celularity Inc
Celularity Inc
Buy
$66.7M
-68.34%
2.28
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$40.0B
318.83%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.8B
166.5%
25.9
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$558.9B
431.9%
47.09
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$103.4B
131.89%
28.81
36.68%

Institutional Holdings

  • Starr International Co., Inc.

    7.02%

  • C V Starr & Co Inc

    3.51%

  • Vanguard Group Inc

    1.71%

  • Geode Capital Management, LLC

    0.45%

  • Renaissance Technologies Corp

    0.39%

  • BlackRock Inc

    0.35%

Company Information

Celularity, Inc. headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified natural killer (NK) cells, genetically-modified NK cells, T-cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (ASCs) targeting indications across cancer, infectious and degenerative diseases. In addition, Celularity develops and manufactures innovative biomaterials also derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it will be able to develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.

Organization
Celularity Inc
Employees
225
CEO
Dr. Robert Joseph Hariri M.D., Ph.D.
Industry
Healthcare

Discover More

FAQs